$31.78
6.97% day before yesterday
Nasdaq, Oct 03, 10:03 pm CET
ISIN
US1421521071
Symbol
CAI

Caris Life Sciences Target price 2025 - Analyst rating & recommendation

Caris Life Sciences Classifications & Recommendation:

Buy
92%
Hold
8%

Caris Life Sciences Price Target

Target Price $39.78
Price $31.78
Potential
Number of Estimates 9
9 Analysts have issued a price target Caris Life Sciences 2026 . The average Caris Life Sciences target price is $39.78. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 12 analysts: 11 Analysts recommend Caris Life Sciences to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Caris Life Sciences stock has an average upside potential 2026 of . Most analysts recommend the Caris Life Sciences stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Million $ 412.26 678.81
34.67% 64.66%
EBITDA Margin -62.34% -1.92%
40.19% 96.92%
Net Margin -91.75% -107.75%
39.27% 17.44%

9 Analysts have issued a sales forecast Caris Life Sciences 2025 . The average Caris Life Sciences sales estimate is

$679m
Unlock
. This is
5.00% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$719m 0.55%
Unlock
, the lowest is
$595m 16.78%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $412m 34.67%
2025
$679m 64.66%
Unlock
2026
$990m 45.81%
Unlock
2027
$1.2b 24.07%
Unlock
2028
$1.4b 17.59%
Unlock

8 Analysts have issued an Caris Life Sciences EBITDA forecast 2025. The average Caris Life Sciences EBITDA estimate is

$-13.0m
Unlock
. This is
95.49% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$23.6m 108.19%
Unlock
, the lowest is
$-78.4m 72.82%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-257m 19.45%
2025
$-13.0m 94.94%
Unlock
2026
$200m 1,640.83%
Unlock
2027
$333m 66.06%
Unlock
2028
$339m 1.94%
Unlock

EBITDA Margin

2024 -62.34% 40.19%
2025
-1.92% 96.92%
Unlock
2026
20.24% 1,154.17%
Unlock
2027
27.09% 33.84%
Unlock
2028
23.49% 13.29%
Unlock

9 Caris Life Sciences Analysts have issued a net profit forecast 2025. The average Caris Life Sciences net profit estimate is

$-731m
Unlock
. This is
28.47% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-251m 75.47%
Unlock
, the lowest is
$-2.4b 138.69%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-378m 18.22%
2025
$-731m 93.36%
Unlock
2026
$77.4m 110.58%
Unlock
2027
$310m 300.63%
Unlock
2028
$509m 64.33%
Unlock

Net Margin

2024 -91.75% 39.27%
2025
-107.75% 17.44%
Unlock
2026
7.82% 107.26%
Unlock
2027
25.24% 222.76%
Unlock
2028
35.27% 39.74%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share $ -1.36 -2.60
18.07% 91.18%
P/E negative
EV/Sales 12.65

9 Analysts have issued a Caris Life Sciences forecast for earnings per share. The average Caris Life Sciences EPS is

$-2.60
Unlock
. This is
28.37% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.89 75.48%
Unlock
, the lowest is
$-8.68 139.12%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.36 18.07%
2025
$-2.60 91.18%
Unlock
2026
$0.28 110.77%
Unlock
2027
$1.10 292.86%
Unlock
2028
$1.81 64.55%
Unlock

P/E ratio

Current
2025
-12.21 39.47%
Unlock
2026
115.47 1,045.70%
Unlock
2027
28.82 75.04%
Unlock
2028
17.54 39.14%
Unlock

Based on analysts' sales estimates for 2025, the Caris Life Sciences stock is valued at an EV/Sales of

12.65
Unlock
and an P/S ratio of
13.17
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 12.02
2025
12.65 5.28%
Unlock
2026
8.68 31.42%
Unlock
2027
7.00 19.40%
Unlock
2028
5.95 14.96%
Unlock

P/S ratio

Current
2025
13.17 5.27%
Unlock
2026
9.03 31.42%
Unlock
2027
7.28 19.40%
Unlock
2028
6.19 14.96%
Unlock

Current Caris Life Sciences Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Citigroup
Locked
Locked
Locked Aug 13 2025
Evercore ISI Group
Locked
Locked
Locked Aug 13 2025
Guggenheim
Locked
Locked
Locked Aug 13 2025
Evercore ISI Group
Locked
Locked
Locked Jul 15 2025
Citigroup
Locked
Locked
Locked Jul 14 2025
Guggenheim
Locked
Locked
Locked Jul 14 2025
JP Morgan
Locked
Locked
Locked Jul 14 2025
Analyst Rating Date
Locked
Citigroup:
Locked
Locked
Aug 13 2025
Locked
Evercore ISI Group:
Locked
Locked
Aug 13 2025
Locked
Guggenheim:
Locked
Locked
Aug 13 2025
Locked
Evercore ISI Group:
Locked
Locked
Jul 15 2025
Locked
Citigroup:
Locked
Locked
Jul 14 2025
Locked
Guggenheim:
Locked
Locked
Jul 14 2025
Locked
JP Morgan:
Locked
Locked
Jul 14 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today